Sanofi India Limited (SANOFI) - Total Liabilities
Based on the latest financial reports, Sanofi India Limited (SANOFI) has total liabilities worth Rs5.06 Billion INR (≈ $54.68 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SANOFI net assets growth trend to track the company's year-over-year net asset growth rate.
Sanofi India Limited - Total Liabilities Trend (2004–2025)
This chart illustrates how Sanofi India Limited's total liabilities have evolved over time, based on quarterly financial data. See Sanofi India Limited free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Sanofi India Limited Competitors by Total Liabilities
The table below lists competitors of Sanofi India Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
engcon AB Cl B
ST:ENGCON-B
|
Sweden | Skr653.00 Million |
|
Xinke Material
SHG:600255
|
China | CN¥2.59 Billion |
|
Ripley Corp
SN:RIPLEY
|
Chile | CL$3.02 Trillion |
|
Standard Motor Products Inc
NYSE:SMP
|
USA | $1.34 Billion |
|
Cablevision Holding SA
BA:CVH
|
Argentina | AR$9.10 Trillion |
|
Genomma Lab Internacional S.A.B. de C.V
MX:LABB
|
Mexico | MX$13.09 Billion |
|
Sichuan Lutianhua Co Ltd
SHE:000912
|
China | CN¥2.74 Billion |
|
Guan Chong Bhd
KLSE:5102
|
Malaysia | RM4.82 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Sanofi India Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SANOFI market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.47 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sanofi India Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sanofi India Limited (2004–2025)
The table below shows the annual total liabilities of Sanofi India Limited from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Rs5.06 Billion ≈ $54.68 Million |
-32.69% |
| 2024-12-31 | Rs7.51 Billion ≈ $81.24 Million |
+7.38% |
| 2023-12-31 | Rs7.00 Billion ≈ $75.66 Million |
-12.10% |
| 2022-12-31 | Rs7.96 Billion ≈ $86.07 Million |
-4.73% |
| 2021-12-31 | Rs8.35 Billion ≈ $90.35 Million |
+4.49% |
| 2020-12-31 | Rs8.00 Billion ≈ $86.46 Million |
-0.32% |
| 2019-12-31 | Rs8.02 Billion ≈ $86.74 Million |
+4.89% |
| 2018-12-31 | Rs7.65 Billion ≈ $82.70 Million |
+1.88% |
| 2017-12-31 | Rs7.51 Billion ≈ $81.17 Million |
-6.69% |
| 2016-12-31 | Rs8.04 Billion ≈ $86.99 Million |
+3.47% |
| 2015-12-31 | Rs7.77 Billion ≈ $84.08 Million |
+4.81% |
| 2014-12-31 | Rs7.42 Billion ≈ $80.22 Million |
+48.92% |
| 2013-12-31 | Rs4.98 Billion ≈ $53.87 Million |
+16.60% |
| 2012-12-31 | Rs4.27 Billion ≈ $46.20 Million |
+10.69% |
| 2011-12-31 | Rs3.86 Billion ≈ $41.74 Million |
-2.11% |
| 2010-12-31 | Rs3.94 Billion ≈ $42.64 Million |
+44.13% |
| 2009-12-31 | Rs2.74 Billion ≈ $29.58 Million |
+15.80% |
| 2008-12-31 | Rs2.36 Billion ≈ $25.55 Million |
+13.19% |
| 2007-12-31 | Rs2.09 Billion ≈ $22.57 Million |
-16.52% |
| 2006-12-31 | Rs2.50 Billion ≈ $27.04 Million |
+46.23% |
| 2005-12-31 | Rs1.71 Billion ≈ $18.49 Million |
+14.30% |
| 2004-12-31 | Rs1.50 Billion ≈ $16.18 Million |
-- |
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targoci… Read more